![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tyratech (DI/S) | LSE:TYR | London | Ordinary Share | COM SHS USD0.001 (DI / REGS) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 2.95 | 2.70 | 3.20 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMTYR TIDMTYRU
RNS Number : 0029Y
TyraTech, Inc.
20 January 2014
20 January 2014
TyraTech, Inc.
("TyraTech" or the "Company")
Vamousse(TM) head lice preventative shampoo coming to market in the USA
TyraTech, Inc. (AIM: TYR and TYRU) a life sciences company focusing on nature-derived insect and parasite control products, is pleased to announce its pioneering, over-the-counter head lice preventative shampoo product, Vamousse(TM), is now listed with the USA Food and Drug Administration ("FDA") and will be available for sale in the USA from the end of Q1 2014. The Vamousse Preventative Shampoo is a new product in the Vamousse range of head lice products and complements the Vamousse Treatment.
The Vamousse(TM) preventative shampoo product is targeting a new market, the prevention rather than the treatment of head lice infestation. The product provides a unique solution to help prevent head lice infestation. The shampoo can be used on a regular basis to prevent head lice infestation in children in at-risk situations (sleep-overs, camps, sports, events with friends, etc.) as well as to protect the whole family when an infestation occurs in one of its members. TyraTech believes that this product has the potential to give it access to a new market segment for prevention and for routine use of the product whereas existing head lice treatments are only used on an emergency basis and only for individuals that are already infested.
In addition, the new Vamousse(TM) preventative shampoo product will enable TyraTech to further expand its market penetration by offering a larger range of products for both head lice treatment and prevention. TytraTech believes that the Vamousse Preventative Shampoo will be distributed initially on-line and in brick-and-mortar distributors in the USA.
Bruno Jactel, Chief Executive Officer, said: "We have been working diligently to accelerate the development of this breakthrough preventative head lice shampoo targeting a new and potentially significant market. We are delighted to announce that we are now FDA listed and ready to launch in the US market. This product will be available soon in traditional retail and internet-based distributors. We feel confident that TyraTech's unique and complete product offering will help us to establish a significant market presence. TyraTech believes it is well positioned to meet market expectations for 2014 revenues."
Further information on Vamousse(TM) is available on the Company's website at:
http://www.tyratech.com/content/company-products/head-lice.asp
For further information please contact:
TyraTech Inc. Alan Reade, Non-Executive Chairman Tel: +44 7841 978709 Bruno Jactel, Chief Executive Officer Tel: +1 919 415 4340 SPARK Advisory Partners Limited, Nominated Adviser Matt Davis / Mark Brady Tel: +44 20 3368 3551 Allenby Capital Limited , Joint Broker Chris Crawford Tel: +44 20 3328 5656 Whitman Howard Limited, Joint Broker Ranald Mc-Gregor Smith / Niall Devins Tel: +44 20 7087 4555 Walbrook, Financial PR and IR Bob Huxford /Guy McDougall (Public Relations) Tel: +44 20 7933 8792 Paul Cornelius (Investor Relations) Tel: +44 20 7933 8794
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLIFSTLIIALIS
1 Year Tyratech Chart |
1 Month Tyratech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions